Company news

BlossomHill Therapeutics, Inc. news in 2026

BlossomHill Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

November 12, 2026

BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC

November 9, 2026

BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting

November 4, 2026

BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference

November 3, 2026

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer

October 22, 2026

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

September 18, 2026

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

September 1, 2026

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

August 19, 2026

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

August 18, 2026

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

August 6, 2026

Decks in 2026